相关实验视频
Updated: May 26, 2025

07:18
Intracellular Refolding Assay
Published on: January 24, 2012
14.1K
治疗耐药性:在癌症中调节进化保守的热冲击蛋白机械
Ilona Skrabalak1, Alicja Rajtak2, Beata Malachowska3
1The First Department of Oncologic Gynecology and Gynecology, Medical University of Lublin, Lublin, Poland.
Cancer letters
|February 22, 2025
概括
热冲击蛋白 (HSP) 帮助癌细胞在治疗中存活下来,导致复发. 针对HSP提供了一个有希望的新策略,以克服癌症药物耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 治疗耐药性是癌症治疗的重要障碍,导致患者复发和死亡率.
- 热冲击蛋白 (HSP) 在癌细胞中被上调,有助于适应瘤微环境 (TME) 压力因素.
- 医疗保健专家在癌症的进展和药物耐药性的发展中发挥着至关重要的作用.
研究的目的:
- 审查HSP在癌症治疗耐药性的作用.
- 为了突出了解HSP机器的最新进展.
- 探索在癌症治疗中针对HSP的治疗潜力.
主要方法:
- 关于HSP和癌症治疗耐药性的现有研究的文献综述.
- 分析HSP为TME应激适应做出贡献的机制.
- 探索针对高水平医生的现有和新兴治疗策略.
主要成果:
- 在癌细胞中,HSP的合成升高,在各种TME条件下促进生存.
- 高血压患者与治疗耐药性的多种机制有关.
- 针对HSP的目标表明克服治疗耐药性的潜力.
结论:
- 高血压患者是癌症治疗耐药性的关键调解者.
- 了解HSP的功能为新的治疗方法提供了洞察力.
- 针对HSP是一个有前途的策略,可以提高癌症治疗效率.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Intrinsic Apoptotic Pathway
6.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.0K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K

